Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRE | P78334 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28165710 | 0.84 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17818478 | 0.84 | ERN1 (0.44) | KDM4EKMT2AMEN1TDP1MAPT | |
| SCHEMBL2921220 | 0.83 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31494238 | 0.83 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1251359 | 0.81 | CYP1A2 (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2472606 | 0.79 | KDM4E (0.46) | CASP7KDM4EKMT2AMEN1GLA | |
| SCHEMBL27899235 | 0.79 | GAA (0.38) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL1149742 | 0.79 | KDM4E (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5672329 | 0.79 | CYP1A2 (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2926609 | 0.79 | KDM4E (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104356002-A | Preparation process of impurities contained in expectorant drug bromhexine hydrochloride | UNIV HEBEI MEDICAL | 2015-02-18 | — | — | CN | claimed |
| US-7582755-B2 | Such as 2-amino-5-(5-cyano-1-methyl-1H-pyrrol-2-yl) benzoic acid methyl ester by reacting cyanopyrrole with coupling agent, reacting with anthranilic alcohol or anthranilic nitro alcohol to form cyanopyrrole substituted anthranilic alcohol or cyanopyrrole substituted anthranilic nitro alcohol, reducing | WYETH (US) | 2009-09-01 | — | — | US | claimed |
| EP-1756095-B1 | CYANOPYRROLE CONTAINING CYCLIC CARBAMATE AND THIOCARBAMATE BIARYLS AND METHODS FOR PREPARING THE SAME | WYETH CORP (US) | 2008-05-21 | — | — | EP | claimed |
| EP-1756095-A2 | CYANOPYRROLE CONTAINING CYCLIC CARBAMATE AND THIOCARBAMATE BIARYLS AND METHODS FOR PREPARING THE SAME | Wyeth (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105739-A2 | CYANOPYRROLE CONTAINING CYCLIC CARBAMATE AND THIOCARBAMATE BIARYLS AND METHODS FOR PREPARING THE SAME | WYETH (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050239779-A1 | Cyanopyrrole-containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same | WYETH (US) | 2005-10-27 | — | — | US | claimed |
| WO-2026101924-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739681-A1 | SUBSTITUTED THIAZOLE COMPOUNDS AS CDK2/4/6 INHIBITORS AND METHODS OF USE THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-12404250-B2 | PARP inhibitors for treating cancer and asthma | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025137329-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2025-05-15 | — | — | US | disclosed |
| CN-111699176-B | Quinazolinones as PARP14 inhibitors | 里邦医疗公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025007859-A1 | SUBSTITUTED THIAZOLE COMPOUNDS AS CDK2/4/6 INHIBITORS AND METHODS OF USE THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-01-09 | — | — | WO | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| CN-1972932-A | Compounds and methods for treating dyslipidemia | LILLY CO ELI (US) | 2007-05-30 | — | — | CN | disclosed |
| EP-1761522-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| CN-1863778-A | Compounds and methods for treating dyslipidemia | LILLY CO ELI (US) | 2006-11-15 | — | — | CN | disclosed |
| CN-1784390-A | Substituted dihydrochinazolines having antiviral properties | BAYER HEALTHCARE AG (DE) | 2006-06-07 | — | — | CN | disclosed |
| WO-2006002342-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-01-05 | — | — | WO | disclosed |
| CN-1134417-A | 2, 8-disubstituted quinazolinones | BAYER AG (DE) | 1996-10-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239779-A1 | Cyanopyrrole-containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same | CBR3, MMAB, CTH | GABRP 231/4885GABRD 668/4885GABRA1 360/4885 |
| US-12404250-B2 | PARP inhibitors for treating cancer and asthma | PARP1, PARP2, PARP11 | GABRP 2696/4885GABRD 4200/4885GABRA1 2586/4885 |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | CETP, APOB, MTTP | GABRP 3179/4885GABRD 4297/4885GABRA1 3521/4885 |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | GABRP 1352/4885GABRD 1207/4885GABRA1 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.